First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation
Journal of the American College of Cardiology · 2023-08 · 82 (5) · 469-471
DOI: 10.1016/j.jacc.2023.05.012 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the American College of Cardiology, 2023-08. Verfasst von Jakub Sroubek und 11 weiteren Autor:innen. Hauptthemen laut MEDLINE: Heart Failure, Tachycardia, Ventricular, Catheter Ablation. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 2 Literaturangaben. Gefördert von: Boston Scientific Corporation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Förderung
- Boston Scientific Corporation
Zitieren
APA
Sroubek, J., Vajapey, R., Sipko, J. J., Soltesz, E. G., Weiss, A. J., Bhargava, M., Hussein, A. A., Kanj, M., Saliba, W. I., Taigen, T. L., Wazni, O. M., & Santangeli, P. (2023). First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation. Journal of the American College of Cardiology, 82(5), 469-471. https://doi.org/10.1016/j.jacc.2023.05.012
Vancouver
Sroubek J, Vajapey R, Sipko JJ, Soltesz EG, Weiss AJ, Bhargava M, et al. First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation. Journal of the American College of Cardiology. 2023;82(5):469-471. doi:10.1016/j.jacc.2023.05.012
BibTeX
@article{Sroubek2023,
author = {Sroubek, Jakub and Vajapey, Ramya and Sipko, Joseph J and Soltesz, Edward G and Weiss, Aaron J and Bhargava, Mandeep and Hussein, Ayman A and Kanj, Mohamed and Saliba, Walid I and Taigen, Tyler L and Wazni, Oussama M and Santangeli, Pasquale},
title = {First-in-Human Experience With Impella 5.0/5.5 for High-Risk Patients With Advanced Heart Failure Undergoing VT Ablation},
journal = {Journal of the American College of Cardiology},
year = {2023},
volume = {82},
number = {5},
pages = {469--471},
doi = {10.1016/j.jacc.2023.05.012}
}
EUVIMED